EUVIMEDEUVIMED entdecken
Open Access

Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy

Beltran Borges iD, Stephen M Brown iD, Wan-Jin Chen, Maria T Clarke iD, Akos Herzeg iD, Jae Hong Park iD, Joshua Ross iD, Lingling Kong iD, Madeline Denton, Amy K Smith iD, Tony Lum iD, Fareha Moulana Zada und 10 weitere

Science Translational Medicine · 2025

DOI: 10.1126/scitranslmed.adv4656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Beltran Borges und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Muscular Atrophy, Spinal, Amniotic Fluid. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurological disorders with onset before or at birth are a leading cause of morbidity and mortality in infants and children. Prenatal treatment has the potential to reduce or prevent irreversible neuronal loss and facilitate normal neurodevelopment. We hypothesized that antisense oligonucleotides (ASOs) delivered to the amniotic fluid by intra-amniotic (IA) injection could safely distribute to the fetal central nervous system (CNS) and provide therapeutic benefit in the motor neuron disease spinal muscular atrophy (SMA), caused by mutations of the survival of motor neuron 1 gene ( SMN1 ), leading to deficiency of SMN protein. Although the splice-switching ASO nusinersen ameliorates SMA when delivered postnatally, substantial deficits can remain in severely affected infants. Here, IA injection of ASOs into two mouse models of severe SMA increased SMN expression in the CNS. In SMAΔ7 mice, which manifest pathology in utero, prenatal treatment improved motor neuron numbers, motor axon development, motor behavioral tests, and survival when compared with those in mice treated postnatally (between P1 and P3). To assess the feasibility of prenatal treatment in a large-animal model, ASOs were delivered midgestation to fetal sheep by IA or intracranial injection. ASOs delivered by IA injection distributed to the spinal cord at therapeutic concentrations and to multiple peripheral tissues without evidence of substantial toxicity to the fetus or mother. These data demonstrated that IA delivery of ASOs holds potential as a minimally invasive approach for prenatal treatment of SMA and possibly other severe, early-onset neurological disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseMuscular Atrophy, SpinalAmniotic FluidAnimalsDisease Models, AnimalMiceFemalePhenotypeMotor NeuronsSurvival of Motor Neuron 1 ProteinPregnancyHumansSheep

Substanzen

Oligonucleotides, AntisenseSurvival of Motor Neuron 1 Protein

Autor:innen und Institutionen

  • Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
  • UCSF Center for Maternal-Fetal Precision Medicine, San Francisco, CA 94158, USA.
  • Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
  • First Affiliated Hospital of Fujian Medical University, Fuzhou 350004, China.
  • Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.

ORCID-Profile: Beltran Borges, Stephen M Brown, Maria T Clarke, Akos Herzeg, Jae Hong Park, Joshua Ross, Lingling Kong, Amy K Smith, Tony Lum, Marco Cordero, John Matson, Stephanie Klein, Adrian R Krainer, Tippi C MacKenzie, Charlotte J Sumner

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Borges, B., Brown, S. M., Chen, W. J., Clarke, M. T., Herzeg, A., Park, J. H., Ross, J., Kong, L., Denton, M., Smith, A. K., Lum, T., Zada, F. M., Cordero, M., Gupta, N., Cook, S. E., Murray, H., Matson, J., Klein, S., Bennett, C. F., …, & Sumner, C. J. (2025). Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adv4656

Vancouver

Borges B, Brown SM, Chen WJ, Clarke MT, Herzeg A, Park JH, et al. Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adv4656

BibTeX
@article{Borges2025,
  author = {Borges, Beltran and Brown, Stephen M and Chen, Wan-Jin and Clarke, Maria T and Herzeg, Akos and Park, Jae Hong and Ross, Joshua and Kong, Lingling and Denton, Madeline and Smith, Amy K and Lum, Tony and Zada, Fareha Moulana and Cordero, Marco and Gupta, Nalin and Cook, Sarah E and Murray, Heather and Matson, John and Klein, Stephanie and Bennett, C Frank and Krainer, Adrian R and MacKenzie, Tippi C and Sumner, Charlotte J},
  title = {Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy},
  journal = {Science Translational Medicine},
  year = {2025},
  doi = {10.1126/scitranslmed.adv4656}
}
Kostenlos starten →